Real-world use of TAR-200 for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-muscle invasive bladder cancer (cancer that has not spread into the bladder muscle).
- You have started your first dose of TAR-200 within the past 6 weeks as part of your regular care.
- If you could become pregnant, you must follow the contraceptive guidelines provided with TAR-200 and talk to your doctor about birth control.
- You must be willing to sign a consent form to participate.
- You cannot be in another clinical trial for bladder cancer right now.
- You cannot have had more than 2 doses of TAR-200 before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
Hear when a new Non-Muscle Invasive Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.